Press release
Eczema Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun
Eczema Pipeline Analysis
Eczema Pipeline constitutes 100+ key companies continuously working towards developing 100+ Eczema treatment therapies, analyzes DelveInsight.
Eczema Overview:
Eczema, also known as atopic dermatitis, is the most common form of dermatitis and arises from a combination of genetic and environmental influences. Although it mainly affects children, adults can also develop the condition. Eczema causes dry, itchy, and inflamed skin that may become infected, often leading to rashes due to persistent scratching. Management primarily involves keeping the skin well-moisturized and using topical steroids during flare-ups.
The condition affects approximately 15-30% of children and 2-10% of adults, with about 60% of cases starting within the first year of life. It is more prevalent in rural areas, indicating environmental triggers. Symptoms include red, itchy rashes, dry or cracked skin, and occasional bleeding. The affected areas vary with age-infants often show symptoms on the cheeks and limbs, while older children and adults typically experience it on the hands, feet, and behind the knees. Intense itching can interfere with sleep and lead to secondary infections.
Treatment is tailored to the severity of symptoms. Mild cases may be managed with moisturizers, while more severe flare-ups require prescription treatments such as topical corticosteroids. Allergists can assist in developing personalized treatment plans. Avoiding triggers like harsh soaps, wool fabrics, dust mites, and pet dander, along with maintaining proper skin hydration, is essential for preventing and managing flare-ups.
Request for a detailed insights report on Eczema pipeline insights https://www.delveinsight.com/report-store/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Eczema Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Eczema Therapeutics Market.
Key Takeaways from the Eczema Pipeline Report
*
DelveInsight's Eczema pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Eczema treatment.
*
In September 2024, the FDA approved Ebglyss (lebrikizumab-lbkz), an IL-13 inhibitor biologic developed by Eli Lilly and Company. It is intended for the treatment of moderate-to-severe atopic dermatitis in adults and children aged 12 and older who weigh at least 88 pounds (40 kg).
*
Key Eczema companies such as Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others are evaluating new drugs for Eczema to improve the treatment landscape.
*
Promising Eczema pipeline therapies in various stages of development include Amlitelimab, BX 005, LP 0145, and others.
Eczema Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Eczema Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Eczema treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Eczema market.
Download our free sample page report on Eczema pipeline insights [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Eczema Emerging Drugs
*
Amlitelimab: Kymab
*
BX 005: BiomX
*
LP 0145: LEO Pharma
Eczema Companies
More than 100 major companies are actively developing treatments for eczema. Among them, LEO Pharma has drug candidates currently in the advanced Phase II stage of development.
DelveInsight's report covers around 75+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Eczema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Eczema Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Eczema Therapies and Key Companies: Eczema Clinical Trials and advancements [https://www.delveinsight.com/report-store/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Eczema Pipeline Therapeutic Assessment
- Eczema Assessment by Product Type
- Eczema By Stage
- Eczema Assessment by Route of Administration
- Eczema Assessment by Molecule Type
Download Eczema Sample report to know in detail about the Eczema treatment market @ Eczema Therapeutic Assessment [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Eczema Current Treatment Patterns
4. Eczema - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Eczema Late-Stage Products (Phase-III)
7. Eczema Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Eczema Discontinued Products
13. Eczema Product Profiles
14. Eczema Key Companies
15. Eczema Key Products
16. Dormant and Discontinued Products
17. Eczema Unmet Needs
18. Eczema Future Perspectives
19. Eczema Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Eczema Pipeline Reports Offerings [https://www.delveinsight.com/report-store/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=eczema-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-kymab-biomx-leo-pharma-glaxosmithkline-arjil-pharmaceuticals-scm-lifescience-sun]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Eczema Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun here
News-ID: 4105419 • Views: …
More Releases from ABNewswire
Newman's Brew Proves Smooth, Flavorful Coffee Begins with Ethical Sourcing and P …
Newman's Brew has built its reputation on delivering the smoothest coffee available by combining organic bean sourcing with fresh-per-order roasting. The rapidly expanding company demonstrates that ethical business practices and exceptional product quality are not mutually exclusive, while supporting abandoned animal feeding programs as part of its commitment to positive social impact.
In an industry where freshness is often sacrificed for operational convenience, Newman's Brew has chosen a different path. The…
Playground Play Equipment Innovation Sets New Benchmark for Safe, Engaging Space …
As schools, communities, and commercial venues worldwide continue to invest in healthier and more inclusive outdoor environments, playground play equipment [https://www.indooroutdoorplayground.com/what-makes-playground-play-equipment-truly-safe-and-engaging/] is entering a new era-one defined by higher safety standards, smarter design, and broader community engagement. Golden Times (Wenzhou Golden Times Amusement Toys CO., LTD.) today announced an expanded product and market strategy focused on delivering next-generation playground solutions that balance safety, durability, and creativity.
Industry expectations for playgrounds have…
Time.so Reports 300% Growth in Business Users
Time.so reports 300% growth in business users as global teams rely on its fast world clock, city times, time zones, and weather for planning.
Jan 31, 2026 - Time.so today announced a 300% increase in business users, reflecting rising demand for dependable time data across distributed teams, global customer support, and cross border operations.
The surge follows a clear shift in how companies schedule work. Meetings span continents. Deadlines move with daylight…
Shaun Savvy Helps Tuckaway Farm in Bentonville, Arkansas Sell Out Two CSA Season …
Buffalo-based SEO consultant Shaun Savvy partnered with Tuckaway Farm in Bentonville, Arkansas to help the farm sell out two consecutive CSA seasons, generating over $80,000 in revenue while spending less than $1,000 on paid advertising through a strategic blend of local SEO, high-intent content, and targeted social media campaigns.
Shaun Savvy, a Buffalo-based SEO and digital marketing consultant, announced a successful local marketing case study showcasing how Tuckaway Farm sold out…
More Releases for Eczema
Global Parents for Eczema Research (GPER) Announces 2025 Childhood Eczema Preven …
Santa Barbara, CA, September 9, 2025 - A decade ago, Global Parents for Eczema Research (GPER) was founded with a simple but powerful mission: to reduce the suffering of children with eczema and to give parents a voice in shaping research priorities. Today, GPER is carrying that mission forward by directly funding innovative science to make rapid progress towards a cure and prevention.
GPER is excited to announce the recipients of…
Hand Eczema Market Massive Growth opportunity Ahead
Introduction
Hand eczema, a chronic inflammatory skin condition affecting the hands, is one of the most common occupational skin disorders worldwide. Characterized by itching, redness, scaling, and painful cracks, it can severely impair daily activities and quality of life. The condition is prevalent among healthcare workers, hairdressers, construction workers, and others exposed to irritants and allergens.
With increasing awareness of skin health, growth in dermatological research, and the introduction of novel therapies…
Codex Labs to Exhibit at the National Eczema Association's Eczema Expo 2025
Scottsdale, Ariz. - July 17th, 2025 - Codex Labs [https://www.codexlabscorp.com/], a biotech skincare company focused on microbiome-friendly solutions, is honored to participate in the National Eczema Association's Eczema Expo 2025 [https://nationaleczema.org/eczema-expo/?gad_source=1&gad_campaignid=22351487646&gbraid=0AAAAAB0npNbWbfjE80zPi-DhIw2YfY2qF&gclid=CjwKCAjw3f_BBhAPEiwAaA3K5GPLZHZHEl6Qy8xrAj3hEWhfW7WDsCE-7pymOFKmLfLmr43e1AAXYhoC90YQAvD_BwE]. Taking place from July 24th to 27th at the Grand Hyatt Scottsdale Resort, individuals impacted by eczema will gather to learn from world-class medical experts and community leaders. The goal of the event is to provide you with support,…
Global Parents for Eczema Research (GPER) Awards Two Grants to Advance Childhood …
Santa Barbara, CA, October 15, 2024 - Global Parents for Eczema Research (GPER), a nonprofit organization dedicated to improving the lives of children suffering from eczema (atopic dermatitis, AD), announced the funding of two groundbreaking research projects as part of its 2024 Childhood Eczema Prevention Grant program. These grants will each provide up to $25,000 to support clinical research focused on preventing eczema in children.
Eczema affects up to 20% of…
Global Parents for Eczema Research (GPER) Announces Childhood Eczema Prevention …
Santa Barbara, CA, March 11, 2024 - Global Parents for Eczema Research (GPER) today announced the release of its Childhood Eczema Prevention Grant aimed at supporting innovative research studies focused on preventing pediatric atopic dermatitis (AD or "eczema"). This funding announcement is aimed at addressing the increasing prevalence of AD among children and at fostering research initiatives with the potential to mitigate the burden on children and families.
"We are dedicated…
Eczema Treatment Market During 2017 to 2025
Eczema, also referred as dermatitis or atopic dermatitis, is a disease which results in inflammation of the skin. Eczema is characterized by rash, red skin, and itchiness. The area of the skin involved may vary from small to the entire body. Few combination of factors such as genetical factor, abnormal function of immune system, environmental factor, defects in skin barrier, and activities may cause the skin to be extremely sensitive.…
